Archive

I recently read that by 2025, 36% of world data will be healthcare data. (Yes, thirty-six percent!). Considering this statistic, now more than ever, it is important that we are working to ensure existing data is utilised to make better safety assessment decisions more quickly - whilst also relying less on animal testing.

Would your toxicology assessments benefit from free access to long-term carcinogenicity study data? The Lhasa Carcinogenicity Database (LCDB) is a widely used, free resource of long-term carcinogenicity study data.

In this article we explore 5 things you should know about the data in the LCDB.

“As Adverse Outcome Pathways (AOPs) move from being an interesting scientific concept, to a useful practical application tool, this is an exciting time for both industry and Lhasa” … Regular Lhasa blog readers will have read this statement within our September blog “Shaping Lhasa Limited’s scientific direction through collaboration”.

It is with great excitement that this month we can provide you with another pioneering update on the topic of our AOP work; Our paper, “Employing an adverse outcome pathway framework for weight-of-evidence assessment with application to the ICH S1B guidance addendum” has now been published in the Regulatory Toxicology and Pharmacology Journal!

“Our technology is designed by scientists, for scientists, in collaboration with industry stakeholders and regulators” …

At Lhasa Limited we often talk about the importance of industry and regulatory input in shaping our scientific direction. This article discusses a few key areas of involvement and collaboration plus, focuses on a recent example, on the topic of Adverse Outcome Pathways (AOPs). Read on to learn more and find out how you can get involved!

In this blog piece, we explore how Derek Nexus performs when evaluated against 7 different in silico skin sensitisation models.

Are you getting the most out of Zeneth, Lhasa’s expert, knowledge-based in silico software for the prediction of forced degradation pathways of organic active pharmaceutical ingredients (APIs)? 

In a world where we are all striving for progress, technology is also advancing quickly.

Like many organisations across the life sciences industry – evidenced by the 82 Amazon Web Service (AWS) life sciences case studies -  Lhasa has adopted cloud, Software as a Service (SaaS), options across three notable areas...

Are you interested in using your data to anticipate and mitigate adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.

Key to the regulatory acceptance of purge arguments is the conservatism within the purge factor scoring system, which for reactivity purge has been demonstrated across a number of publications and is consistently implemented across the pharmaceutical industry through the development of a collective understanding of and how they should be applied.

Likewise, when volatility purge scoring is relatively simple to understand and apply, particularly using the scoring thresholds originally proposed by Teasdale et al.

However, through our interactions with Mirabilis users, regulators, and other members of the purge community, it has become increasingly apparent that the same cannot be said of solubility purge scoring. Lhasa have therefore identified the huge value to the community of developing an accepted best practice, incorporating both the application of solubility purge scoring and, where appropriate, provision of a clear justification of the purge factor assigned.

Coronaviruses are a large family of viruses which can affect humans or other species and can range anywhere from a mild illness such as the common cold to more severe illnesses such as Severe Acute Respiratory Syndrome (SARS). Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).